Article
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2017
Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem J-L, Emile J-F, Mulot C, Fratté S, Levaché C-B, Saban-Roche L, Thaler J, Petersen L N, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P
Abstract excerpt
Background: RAS mutations have been shown to confer resistance to anti- epidermal growth factor receptor (EGFR) treatment. We analysed the results of the PETACC8 trial (cetuximab + FOLFOX vs FOLFOX) in full RAS and BRAF wildtype (WT) patients (pts) with resected stage III colon cancer. Patients and methods: Exons 2, 3 and 4 of KRAS and NRAS, and BRAF exons 11 and 15, were sequenced using the Ampliseq colon-lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.